» Articles » PMID: 26252058

GLP-1 Increases Preovulatory LH Source and the Number of Mature Follicles, As Well As Synchronizing the Onset of Puberty in Female Rats

Overview
Journal Endocrinology
Specialty Endocrinology
Date 2015 Aug 8
PMID 26252058
Citations 32
Authors
Affiliations
Soon will be listed here.
Abstract

Control of estrous cycle and reproductive capacity involves a large number of central and peripheral factors, integrating numerous nutritional and metabolic signals. Here we show that glucagon-like peptide-1 (GLP-1), a peptide with anorexigenic and insulinotropic actions, and the GLP-1 receptor agonist Exendin-4 (Ex4) exert a regulatory influence on the gonadal axis, in both adult and prepubertal female rats. In adult rats, Glp-1 receptor expression varies during the estrous cycle at the hypothalamus, pituitary, and ovary. Furthermore, acute treatment with GLP-1 in the morning proestrus doubled the amplitude of the preovulatory LH surge, as well as influencing estradiol and progesterone levels along the estrous cycle. These changes provoked an important increase in the number of Graafian follicles and corpora lutea, as well as in the litter size. Conversely, Ex4 diminished the levels of LH, later producing a partial blockade at the preovulatory surge, yet not affecting either the number of mature follicles or corpora lutea. Chronic administration of low doses of GLP-1 to prepubertal rats synchronized vaginal opening and increased LH levels on the 35th day of life, yet at these doses it did not modify their body weight, food intake, or ovarian and uterine weight. By contrast, chronic exposure to Ex4 produced a significant reduction in ovarian and uterine weight, and serum LH, and the animals treated chronically with Ex4 showed no vaginal opening in the period studied. Overall, our results demonstrate that GLP-1 and Ex4 act on the gonadal axis, involving the hypothalamic kisspeptin system, to influence reproductive efficiency in female rats.

Citing Articles

Metabolic control of ovarian function through the sympathetic nervous system: role of leptin.

Astudillo-Guerrero C, Paredes A, Escobar J, Fernandois D, Barra R, Cruz G Front Endocrinol (Lausanne). 2025; 15:1484939.

PMID: 39963180 PMC: 11830616. DOI: 10.3389/fendo.2024.1484939.


GLP-1 and Its Analogs: Does Sex Matter?.

Borchers S, Skibicka K Endocrinology. 2024; 166(2).

PMID: 39715341 PMC: 11733500. DOI: 10.1210/endocr/bqae165.


The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation.

Sola-Leyva A, Pathare A, Apostolov A, Aleksejeva E, Kask K, Tammiste T Acta Obstet Gynecol Scand. 2024; 104(2):258-266.

PMID: 39696822 PMC: 11782050. DOI: 10.1111/aogs.15010.


The gut microbiota: emerging biomarkers and potential treatments for infertility-related diseases.

Wang M, Zheng L, Ma S, Zhao D, Xu Y Front Cell Infect Microbiol. 2024; 14:1450310.

PMID: 39391885 PMC: 11464459. DOI: 10.3389/fcimb.2024.1450310.


Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy.

Sanchez-Garrido M, Serrano-Lopez V, Ruiz-Pino F, Vazquez M, Rodriguez-Martin A, Torres E Nat Commun. 2024; 15(1):8498.

PMID: 39353946 PMC: 11445520. DOI: 10.1038/s41467-024-52898-y.